Treatment of advanced thyroid cancer: role of molecularly targeted therapies

Targeted Oncology

Volumn 10, Issue 3, 2015, Pages 311-324

  Covell, Lorinda L ^a   Ganti, Apar Kishor ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Molecularly targeted therapies; Multi kinase inhibitors; Thyroid cancer

Indexed keywords

AXITINIB; BORTEZOMIB; CABOZANTINIB; CARBOPLATIN; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; CROLIBULIN; EVEROLIMUS; IMATINIB; LENVATINIB; LIVER ENZYME; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; PACLITAXEL; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; SELUMETINIB; SORAFENIB; SUNITINIB; TIPIFARNIB; VANDETANIB; VASCULOTROPIN; ANILIDE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; IMETELSTAT; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; NICOTINAMIDE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; RET PROTEIN, HUMAN; SULFONAMIDE; VASCULOTROPIN A;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; CARCINOGENESIS; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOPIGMENTATION; LEUKOPENIA; LOSS OF APPETITE; LYMPHOCYTOPENIA; MOLECULARLY TARGETED THERAPY; MORNING DOSAGE; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; RADIOSENSITIZATION; RASH; RET GENE; REVIEW; SIDE EFFECT; SKIN CARCINOMA; SKIN DEFECT; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CARCINOMA, NEUROENDOCRINE; DNA MUTATIONAL ANALYSIS; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GENETICS; METABOLISM; PROCEDURES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; UNITED STATES;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, NEUROENDOCRINE; DNA MUTATIONAL ANALYSIS; DRUG APPROVAL; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES; PYRIMIDINES; PYRROLES; QUINAZOLINES; QUINOLINES; SULFONAMIDES; THYROID NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84940894311     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0331-z     Document Type: Review

References (79)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208
2. Olaleye O, Ekrikpo U, Moorthy R, Lyne O, Wiseberg J, Black M, Mitchell D (2011) Increasing incidence of differentiated thyroid cancer in South East England: 1987-2006. Eur Arch Otorhinolaryngol Off J Eur Fed Otorhinolaryngol Soc 268(6):899–906. doi:10.1007/s00405-010-1416-7
3. Cramer JD, Fu P, Harth KC, Margevicius S, Wilhelm SM (2010) Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery 148(6):1147–1152. doi:10.1016/j.surg.2010.10.016, discussion 1152-1143
4. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N, Zhang Y (2009) International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control CCC 20(5):525–531. doi:10.1007/s10552-008-9260-4
5. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa SS (2009) Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 18(3):784–791. doi:10.1158/1055-9965.EPI-08-0960
6. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B, Guilhem I (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol 48(3):265–273
7. Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 83(12):2638–2648
8. Sherman SI (2003) Thyroid carcinoma. Lancet 361(9356):501–511
9. Ronga G, Filesi M, Montesano T, Di Nicola AD, Pace C, Travascio L, Ventroni G, Antonaci A, Vestri AR (2004) Lung metastases from differentiated thyroid carcinoma. A 40 years’ experience. Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med 48(1):12–19
10. Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6(4):292–306. doi:10.1038/nrc1836
11. Sherman SI (2010) Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol 22(6):464–468. doi:10.1016/j.clon.2010.03.014
12. Fagin JA, Mitsiades N (2008) Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 22(6):955–969. doi:10.1016/j.beem.2008.09.017
13. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H (1988) Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3(5):571–578
14. Runeberg-Roos P, Saarma M (2007) Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Ann Med 39(8):572–580. doi:10.1080/07853890701646256
15. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93(3):682–687. doi:10.1210/jc.2007-1714
16. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H et al (1994) Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6(1):70–74. doi:10.1038/ng0194-70
17. Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, Bugalho MJ, Leite V (2009) Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100(11):1777–1783. doi:10.1038/sj.bjc.6605056
18. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63(7):1454–1457
19. Meinkoth JL (2004) Biology of Ras in thyroid cells. Cancer Treat Res 122:131–148
20. Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16(1):17–44. doi:10.1677/ERC-08-0154
21. Ciampi R, Nikiforov YE (2007) RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148(3):936–941. doi:10.1210/en.2006-0921
22. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A (2007) The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246(3):466–470. doi:10.1097/SLA.0b013e318148563d, discussion 470-461
23. Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12(2):245–262. doi:10.1677/erc.1.0978
24. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F (2008) BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93(10):3943–3949. doi:10.1210/jc.2008-0607
25. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88(11):5399–5404. doi:10.1210/jc.2003-030838
26. Saji M, Ringel MD (2010) The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 321(1):20–28. doi:10.1016/j.mce.2009.10.016
27. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69(11):4885–4893. doi:10.1158/0008-5472.CAN-09-0727
28. Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G, Fusco A, Viglietto G (2000) PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 19(28):3146–3155. doi:10.1038/sj.onc.1203633
29. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C (1997) Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57(21):4710–4713
30. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070):967–974. doi:10.1038/nature04483
31. Espinosa AV, Porchia L, Ringel MD (2007) Targeting BRAF in thyroid cancer. Br J Cancer 96(1):16–20. doi:10.1038/sj.bjc.6603520
32. Lin JD, Chao TC (2005) Vascular endothelial growth factor in thyroid cancers. Cancer Biother Radiopharm 20(6):648–661. doi:10.1089/cbr.2005.20.648
33. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL (2010) Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid Off J Am Thyroid Assoc 20(8):863–871. doi:10.1089/thy.2009.0417
34. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G et al (1995) Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11(8):1569–1579
35. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O’Dwyer PJ, Brose MS (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(29):4714–4719. doi:10.1200/JCO.2008.16.3279
36. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH (2009) Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(10):1675–1684. doi:10.1200/JCO.2008.18.2717
37. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW (2009) Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol Eur Fed Endocr Soc 161(6):923–931. doi:10.1530/EJE-09-0702
38. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E (2012) Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol Eur Fed Endocr Soc 167(5):643–650. doi:10.1530/EJE-12-0405
39. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM (2011) Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol Eur Fed Endocr Soc 165(2):315–322. doi:10.1530/EJE-11-0129
40. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R (2011) Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96(4):997–1005. doi:10.1210/jc.2010-1899
41. Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade JL III, Ivy SP, Villaflor VM, Seiwert TY, Nichols K, Vokes EE (2008) Phase 2 study of sunitinib in refractory thyroid cancer. ASCO Meet Abstr 26(15_suppl):6025
42. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG (2010) Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res Off J Am Assoc Cancer Res 16(21):5260–5268. doi:10.1158/1078-0432.CCR-10-0994
43. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented G, Mayo Clinic Cancer C, Mayo Phase C (2010) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11(10):962–972. doi:10.1016/S1470-2045(10)70203-5
44. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol Off J Am Soc Clin Oncol 26(29):4708–4713. doi:10.1200/JCO.2007.15.9566
45. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gomez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ (2012) Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 13(9):897–905. doi:10.1016/S1470-2045(12)70335-2
46. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ, Motesanib Thyroid Cancer Study G (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359(1):31–42. doi:10.1056/NEJMoa075853
47. Lim SM, Chang H, Yoon MJ, Hong YK, Kim H, Chung WY, Park CS, Nam KH, Kang SW, Kim MK, Kim SB, Lee SH, Kim HG, Na II, Kim YS, Choi MY, Kim JG, Park KU, Yun HJ, Kim JH, Cho BC (2013) A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol Off J Eur Soc Med Oncol ESMO 24(12):3089–3094. doi:10.1093/annonc/mdt379
48. Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O’Connor W, Weck KE, Cohen RB, Cohen EE (2012) Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res Off J Am Assoc Cancer Res 18(7):2056–2065. doi:10.1158/1078-0432.CCR-11-0563
49. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Pena C, Molnar I, Schlumberger MJ, on behalf of the Di (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. doi:10.1016/S0140-6736(14)60421-9
50. Brose MS, Jarzab B, Elisei R, Siena S, Bastholt L, De La Fouchardiere C, Pacini F, Paschke R, Nutting C, Shong YK, Sherman SI, Smit JW, Chung JW, Kappeler C, Molnar I, Schlumberger M (2014) Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial. ASCO Meet Abstr 32(15_suppl):6060
51. Brose MS, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung JW, Siedentop H, Molnar I, Schlumberger M (2013) Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial. ASCO Meet Abstr 31(18_suppl):4
52. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Dutcus CE, de las Heras B, Zhu J, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim S-B, Krzyzanowska MK, Sherman SI (2014) A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). ASCO Meet Abstr 32(18_suppl):LBA6008
53. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099–7109
54. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM (2009) Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 7(1):20–23. doi:10.3816/CGC.2009.n.003
55. Brose MS, Troxel AB, Redlinger M, Harlacker K, Redlinger C, Chalian AA, Flaherty KT, Loevner LA, Mandel SJ, O’Dwyer PJ (2009) Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients. ASCO Meet Abstr 27(15S):6002
56. Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, Tsuruoka A (2013) Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 340(1):97–103. doi:10.1016/j.canlet.2013.07.007
57. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M (2006) An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91(10):4070–4076. doi:10.1210/jc.2005-2845
58. Capdevila J, Trigo Perez JM, Aller J, Manzano JL, Garcia Adrian S, Zafon C, Reig O, Bohn U, Cillan E, Duran M, Gonzalez Astorga B, Lopez A, Javier M, Porras I, Reina JJ, Palacios N, Grande E, Grau JJ (2014) Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). ASCO Meet Abstr 32(15_suppl):6027
59. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62(24):7284–7290
60. Harvey RD, Kauh JS, Ramalingam SS, Lewis CM, Chen Z, Lonial S, Blount IC, Shin DM, Khuri FR, Owonikoko TK (2010) Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer. ASCO Meet Abstr 28(15_suppl):5589
61. Harvey RD, Owonikoko TK, Lewis CM, Akintayo A, Chen Z, Tighiouart M, Ramalingam SS, Fanucchi MP, Nadella P, Rogatko A, Shin DM, El-Rayes B, Khuri FR, Kauh JS (2013) A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. Br J Cancer 108(4):762–765. doi:10.1038/bjc.2012.604
62. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Dominguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368(7):623–632. doi:10.1056/NEJMoa1209288
63. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(5):767–772. doi:10.1200/JCO.2009.23.6604
64. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R (2010) Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95(6):2664–2671. doi:10.1210/jc.2009-2461
65. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol Off J Am Soc Clin Oncol 29(19):2660–2666. doi:10.1200/JCO.2010.32.4145
66. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(14):2323–2330. doi:10.1200/JCO.2009.25.0068
67. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(23):3794–3801. doi:10.1200/JCO.2008.18.7815
68. De Souza JA, Busaidy N, Zimrin A, Seiwert TY, Villaflor VM, Poluru KB, Reddy PL, Nam J, Vokes EE, Cohen EE (2010) Phase II trial of sunitinib in medullary thyroid cancer (MTC). ASCO Meet Abstr 28(15_suppl):5504
69. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 30(2):134–141. doi:10.1200/JCO.2011.35.5040
70. Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol Off J Am Soc Clin Oncol 31(29):3639–3646. doi:10.1200/JCO.2012.48.4659
71. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62(16):4645–4655
72. Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, Worden FP (2010) A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid Off J Am Thyroid Assoc 20(9):975–980. doi:10.1089/thy.2010.0057
73. Podtcheko A, Ohtsuru A, Namba H, Saenko V, Starenki D, Palona I, Sedliarou I, Rogounovitch T, Yamashita S (2006) Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells. Radiat Res 165(1):35–42
74. Capdevila J, Iglesias L, Halperin I, Segura A, Martinez-Trufero J, Vaz MA, Corral J, Obiols G, Grande E, Grau JJ, Tabernero J (2012) Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 19(2):209–216. doi:10.1530/ERC-11-0351
75. Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, Wasman J, Dowlati A, Remick SC (2013) Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid Off J Am Thyroid Assoc 23(5):600–604. doi:10.1089/thy.2012.0103
76. Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, Karlin NJ, Traynor AM, Kumar P, Goh BC, Lim WT, Bossou AR, Isham CR, Webster KP, Kukla AK, Bieber C, Burton JK, Harris P, Erlichman C, Mayo Phase C, Mayo Clinic Endocrine Malignances Disease Oriented G (2012) A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 97(9):3179–3184. doi:10.1210/jc.2012-1520
77. Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, Licitra L, Remick SC (2014) Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid Off J Am Thyroid Assoc 24(2):232–240. doi:10.1089/thy.2013.0078
78. Gramza AW, Balasubramaniam S, Fojo AT, Ward J, Wells SA (2013) Phase I/II trial of crolibulin and cisplatin in solid tumors with a focus on anaplastic thyroid cancer: phase I results. ASCO Meet Abstr 31(15_suppl):6074
79. Wunderlich A, Khoruzhyk M, Roth S, Ramaswamy A, Greene BH, Doll D, Bartsch DK, Hoffmann S (2013) Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer. J Surg Res 185(2):676–683. doi:10.1016/j.jss.2013.06.017